Clinical trial
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic…
NCT00118157 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00118157 |
|---|---|
| Title | Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen |
| Official title | A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate |
| Enrollment | 19 |
| Start date | May 1, 2005 |
| Primary completion | Jul 1, 2011 |
| Completion | Sep 1, 2014 |
| First posted | Jul 11, 2005 |
| Last update posted | Dec 4, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: